Advertisement

Topics

Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England.

06:00 EDT 25th September 2010 | BioPortfolio

Summary of "Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England."

Pneumococcal conjugate vaccine to 7 capsular types has been highly effective in the US since its introduction in 2000. The same vaccine was adopted by the UK in 2006. Ongoing surveillance since 1995 of invasive pneumococcal disease in Oxfordshire, UK, allowed assessment of the impact of vaccine intervention. The vaccine significantly reduced invasive pneumococcal disease among the target group, children less than 2 years; incidence rate ratio (IRR)=0.62 [95%CI 0.43-0.90] (p=0.008) comparing the 3 years pre- and post-implementation with a residual incidence of 22.4/100,000 children. The reduction was even greater when comparing 11 years pre with the 3 years post implementation of vaccine; IRR=0.53 [0.39- 0.70] p<0.0001. There was a marked direct effect of the vaccine evidenced by substantial reductions in the 7 serotypes contained in the vaccine. There was also a clear reduction in invasive pneumococcal disease for those serotypes contained in the vaccine among those older than 2 years when comparing both the 3 and 11 year pre PCV7 time periods with IRR=0.57 [0.47-0.69] p<0.0001 and IRR=0.50 [0.43-0.58] p<0.0001 respectively, indicating a strong herd effect. There was a significant, though moderate, rise in the serotypes not contained in the vaccine, with clear evidence for replacement in some serotypes.

Affiliation

1 University of Oxford;

Journal Details

This article was published in the following journal.

Name: Journal of medical microbiology
ISSN: 1473-5644
Pages:

Links

DeepDyve research library

PubMed Articles [27690 Associated PubMed Articles listed on BioPortfolio]

Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.

The invasive pneumococcal diseases (IPDs) caused by Streptococcus pneumoniae pose an enormous threat to children under 5 years of age. However, routine use of pneumococcal conjugate vaccines could a...

Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.

The 13-valent pneumococcal conjugate-vaccine (PCV13) was effective in preventing vaccine-type Community-Acquired Pneumonia (VT-CAP) and Invasive Pneumococcal Disease (VT-IPD) in elderly subjects, but ...

Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients.

Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13-valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in h...

Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi.

Pneumococcal infections cause a high death toll in Sub Saharan Africa (SSA) but the recently rolled out pneumococcal conjugate vaccines (PCV) will reduce the disease burden. To better understand the p...

Invasive Pneumococcal Disease in Infants Aged 0-60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era.

We identified 53 infants aged 0-60 days with invasive pneumococcal disease (IPD) at 8 children's hospitals in the United States (2005-2015). After the introduction of 13-valent pneumococcal conjugate ...

Clinical Trials [9840 Associated Clinical Trials listed on BioPortfolio]

Study Evaluating Immune Response of Children Revaccinated With Pneumococcal Conjugate Vaccine

The primary purpose of this study is to characterize the immune response to a single dose of 13-valent pneumococcal conjugate vaccine (13vPnC) in children previously vaccinated with a prim...

Effect of Two Versus Three Pneumococcal Conjugate Vaccinations

Two( 2) or three (3) instead of four vaccinations before the age of 6 months with pneumococcal conjugate vaccine are presumed to protect children against invasive pneumococcal disease like...

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine Administered to Infants in Korea

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate va...

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subje...

Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomita...

Medical and Biotech [MESH] Definitions

A pneumococcal vaccine which 7 pneumococcal serotypes (6B, 14, 19F, 23F, 18C, 4, 9V), each conjugated individually to the outer membrane protein complex of NEISSERIA MENINGITIDIS.

A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.

A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)

An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.

A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topic

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...


Searches Linking to this Article